Cost Insights: Breaking Down AstraZeneca PLC and Regeneron Pharmaceuticals, Inc.'s Expenses

AstraZeneca vs. Regeneron: A Decade of Cost Dynamics

__timestampAstraZeneca PLCRegeneron Pharmaceuticals, Inc.
Wednesday, January 1, 20145842000000205018000
Thursday, January 1, 20154646000000392709000
Friday, January 1, 20164126000000299694000
Sunday, January 1, 20174318000000397061000
Monday, January 1, 20184936000000434100000
Tuesday, January 1, 20194921000000782200000
Wednesday, January 1, 202052990000001119900000
Friday, January 1, 2021124370000002437500000
Saturday, January 1, 2022123910000001560400000
Sunday, January 1, 202380400000001815800000
Monday, January 1, 2024102070000001970500000
Loading chart...

In pursuit of knowledge

Cost Insights: AstraZeneca vs. Regeneron

In the ever-evolving pharmaceutical industry, understanding cost structures is crucial. AstraZeneca PLC and Regeneron Pharmaceuticals, Inc. have shown distinct trends in their cost of revenue from 2014 to 2023. AstraZeneca's expenses surged by over 100% from 2014 to 2021, peaking in 2021 with a cost of revenue nearly three times that of 2014. This reflects their aggressive expansion and investment in R&D. In contrast, Regeneron, while starting with a modest cost base, saw a consistent increase, reaching its highest in 2021, marking a 1,100% rise from 2014. This growth underscores Regeneron's strategic scaling and innovation efforts. By 2023, both companies adjusted their spending, with AstraZeneca reducing costs by 35% from its peak, while Regeneron maintained a steady trajectory. These insights highlight the dynamic nature of pharmaceutical financial strategies over the past decade.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025